Reenacting and amending the act of July 7, 2017 (P.L.285, No.14), entitled "An act establishing the Rare Disease Advisory Council and providing for its powers and duties; and providing for duties of the Department of Health, the Insurance Department, the Department of Human Services and the Department of Education."
HB1527 reenacts and amends Pennsylvania’s Rare Disease Advisory Council Act. The bill keeps the Rare Disease Advisory Council in place, updates its membership, and extends the council’s expiration date from June 30, 2025 to July 1, 2028. It also makes the act effective immediately and applies the extension retroactively to June 30, 2025 so the council’s authority continues without interruption.
The bill expands the council’s membership by adding four legislative appointees: one each appointed by the majority and minority leaders of the Senate and the House. It also preserves the existing mix of state officials, clinicians, researchers, industry representatives, patients, parents, hospitals, insurers, and patient organizations. The council’s core duties remain focused on studying rare diseases in Pennsylvania, coordinating with state and federal agencies, identifying best practices, improving data collection, and reporting on the needs of the rare disease community.
The bill primarily affects the Rare Disease Advisory Council Act by reenacting its provisions, extending its sunset date, and revising council membership and reporting structure. It does not create a new program, but it continues and formalizes the council’s authority to advise the Department of Health, the General Assembly, and related agencies on rare disease policy, data collection, treatment access, and public awareness. It also preserves existing orders, rules, contracts, and obligations under the prior act, minimizing any legal gap in the council’s operations.
The available voting history shows strong bipartisan support and no recorded opposition. The bill passed committee and floor votes in the House unanimously, and the Senate Health and Human Services Committee also reported the amended bill unanimously. That pattern suggests broad agreement that the council should continue and that its work on rare diseases remains worthwhile and noncontroversial.
There is little evidence of substantive controversy in the available record. The only notable policy change is the addition of four legislative appointees to the council, which may reflect an effort to increase legislative oversight or representation, but no opposition is shown in the votes provided. The other likely point of interest is the extension of the council’s sunset date and retroactive continuation, which appears intended to avoid any lapse in the council’s authority rather than to change its mission.